Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III randomized open-label study of PM8002 + paclitaxel versus chemotherapy as second-line treatment for small cell lung cancer
CTR20233984Phase 3Suspended
- Sponsor
- Biotheus
- Start
- Nov 2024
- Modality
- Small Molecules, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of pumitamig, paclitaxel, topotecan in small cell lung cancer (SCLC), sponsored by Biotheus. Started Nov 2024; status: suspended.
02
Drugs
pumitamigpaclitaxeltopotecan
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on CTR20233984.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20233984.